Latest News and Press Releases
Want to stay updated on the latest news?
-
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
-
European Medicines Agency Awards Orphan Status to NurExone's ExoPTEN for Spinal Cord Injury, Paving the Way to European Market Entry
-
NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update
-
NurExone’s Groundbreaking Exosome Therapies to be Showcased at Fall U.S. Conferences
-
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
-
NurExone Biologic Enhances Visibility in Pharmaceutical Industry with Technological Presentations at Major Global Events
-
NurExone demonstrates a longer timeframe of ExoPTEN treatment can be effectively administered post Spinal-Cord Injury
-
NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
NurExone Biologic to present its innovative ExoPTEN therapy at key September conferences in Boston and New York, showcasing its leadership in regenerative
-
NurExone’s reliable production from diverse biological sources allows NurExone to optimize exosome production with consistency and efficiency